Carlsmed (CARL) Competitors

$11.01 +0.25 (+2.32%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$11.36 +0.35 (+3.17%)

As of 05/15/2026 06:42 PM Eastern

CARL vs. TNDM, BFLY, INMD, BVS, and SGP

Should you buy Carlsmed stock or one of its competitors? MarketBeat compares Carlsmed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Carlsmed include Tandem Diabetes Care (TNDM), Butterfly Network (BFLY), InMode (INMD), Bioventus (BVS), and Spyglass Pharma (SGP). These companies are all part of the "medical equipment" industry.

How does Carlsmed compare to Tandem Diabetes Care?

Tandem Diabetes Care (NASDAQ:TNDM) and Carlsmed (NASDAQ:CARL) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

Tandem Diabetes Care has a net margin of -9.20% compared to Carlsmed's net margin of -57.76%. Tandem Diabetes Care's return on equity of -53.88% beat Carlsmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tandem Diabetes Care	-9.20%	-53.88%	-7.88%
Carlsmed	-57.76%	-60.74%	-29.84%

Tandem Diabetes Care presently has a consensus price target of $29.89, suggesting a potential upside of 133.19%. Carlsmed has a consensus price target of $19.33, suggesting a potential upside of 75.60%. Given Tandem Diabetes Care's stronger consensus rating and higher probable upside, equities analysts plainly believe Tandem Diabetes Care is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tandem Diabetes Care	1 Sell rating(s)	10 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.52
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Tandem Diabetes Care had 12 more articles in the media than Carlsmed. MarketBeat recorded 13 mentions for Tandem Diabetes Care and 1 mentions for Carlsmed. Carlsmed's average media sentiment score of 1.44 beat Tandem Diabetes Care's score of 0.85 indicating that Carlsmed is being referred to more favorably in the news media.

Company	Overall Sentiment
Tandem Diabetes Care	Positive
Carlsmed	Positive

Carlsmed has lower revenue, but higher earnings than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tandem Diabetes Care	$1.03B	0.85	-$204.71M	-$1.40	N/A
Carlsmed	$50.51M	5.92	-$29.63M	-$2.51	N/A

Summary

Tandem Diabetes Care beats Carlsmed on 10 of the 14 factors compared between the two stocks.

How does Carlsmed compare to Butterfly Network?

Butterfly Network (NYSE:BFLY) and Carlsmed (NASDAQ:CARL) are both small-cap medical equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, risk and media sentiment.

Carlsmed has lower revenue, but higher earnings than Butterfly Network. Butterfly Network is trading at a lower price-to-earnings ratio than Carlsmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Butterfly Network	$97.61M	9.93	-$77.06M	-$0.30	N/A
Carlsmed	$50.51M	5.92	-$29.63M	-$2.51	N/A

Carlsmed has a net margin of -57.76% compared to Butterfly Network's net margin of -73.63%. Butterfly Network's return on equity of -34.41% beat Carlsmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Butterfly Network	-73.63%	-34.41%	-23.91%
Carlsmed	-57.76%	-60.74%	-29.84%

In the previous week, Butterfly Network had 2 more articles in the media than Carlsmed. MarketBeat recorded 3 mentions for Butterfly Network and 1 mentions for Carlsmed. Carlsmed's average media sentiment score of 1.44 beat Butterfly Network's score of 0.48 indicating that Carlsmed is being referred to more favorably in the news media.

Company	Overall Sentiment
Butterfly Network	Neutral
Carlsmed	Positive

Butterfly Network presently has a consensus price target of $5.56, suggesting a potential upside of 46.19%. Carlsmed has a consensus price target of $19.33, suggesting a potential upside of 75.60%. Given Carlsmed's stronger consensus rating and higher probable upside, analysts plainly believe Carlsmed is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Butterfly Network	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

37.9% of Butterfly Network shares are held by institutional investors. 25.2% of Butterfly Network shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Butterfly Network beats Carlsmed on 8 of the 14 factors compared between the two stocks.

How does Carlsmed compare to InMode?

Carlsmed (NASDAQ:CARL) and InMode (NASDAQ:INMD) are both small-cap medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

InMode has higher revenue and earnings than Carlsmed. Carlsmed is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carlsmed	$50.51M	5.92	-$29.63M	-$2.51	N/A
InMode	$374.64M	2.35	$93.83M	$1.36	10.22

InMode has a net margin of 23.27% compared to Carlsmed's net margin of -57.76%. InMode's return on equity of 13.47% beat Carlsmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carlsmed	-57.76%	-60.74%	-29.84%
InMode	23.27%	13.47%	11.95%

In the previous week, InMode had 3 more articles in the media than Carlsmed. MarketBeat recorded 4 mentions for InMode and 1 mentions for Carlsmed. Carlsmed's average media sentiment score of 1.44 beat InMode's score of 0.61 indicating that Carlsmed is being referred to more favorably in the media.

Company	Overall Sentiment
Carlsmed	Positive
InMode	Positive

Carlsmed currently has a consensus target price of $19.33, suggesting a potential upside of 75.60%. InMode has a consensus target price of $16.00, suggesting a potential upside of 15.11%. Given Carlsmed's stronger consensus rating and higher probable upside, analysts plainly believe Carlsmed is more favorable than InMode.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
InMode	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

68.0% of InMode shares are owned by institutional investors. 6.9% of InMode shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

InMode beats Carlsmed on 10 of the 15 factors compared between the two stocks.

How does Carlsmed compare to Bioventus?

Carlsmed (NASDAQ:CARL) and Bioventus (NASDAQ:BVS) are both small-cap manufacturing companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

62.9% of Bioventus shares are owned by institutional investors. 33.0% of Bioventus shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Bioventus has higher revenue and earnings than Carlsmed. Carlsmed is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carlsmed	$50.51M	5.92	-$29.63M	-$2.51	N/A
Bioventus	$568.09M	1.56	$22.73M	$0.41	25.80

Bioventus has a net margin of 4.94% compared to Carlsmed's net margin of -57.76%. Bioventus' return on equity of 29.97% beat Carlsmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carlsmed	-57.76%	-60.74%	-29.84%
Bioventus	4.94%	29.97%	9.52%

In the previous week, Bioventus had 1 more articles in the media than Carlsmed. MarketBeat recorded 2 mentions for Bioventus and 1 mentions for Carlsmed. Carlsmed's average media sentiment score of 1.44 beat Bioventus' score of 0.63 indicating that Carlsmed is being referred to more favorably in the media.

Company	Overall Sentiment
Carlsmed	Positive
Bioventus	Positive

Carlsmed currently has a consensus target price of $19.33, suggesting a potential upside of 75.60%. Bioventus has a consensus target price of $14.00, suggesting a potential upside of 32.33%. Given Carlsmed's higher probable upside, analysts plainly believe Carlsmed is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Bioventus	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Bioventus beats Carlsmed on 12 of the 15 factors compared between the two stocks.

How does Carlsmed compare to Spyglass Pharma?

Carlsmed (NASDAQ:CARL) and Spyglass Pharma (NASDAQ:SGP) are both small-cap manufacturing companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

Spyglass Pharma has lower revenue, but higher earnings than Carlsmed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carlsmed	$50.51M	5.92	-$29.63M	-$2.51	N/A
Spyglass Pharma	N/A	N/A	N/A	N/A	N/A

Spyglass Pharma has a net margin of 0.00% compared to Carlsmed's net margin of -57.76%. Spyglass Pharma's return on equity of 0.00% beat Carlsmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Carlsmed	-57.76%	-60.74%	-29.84%
Spyglass Pharma	N/A	N/A	N/A

In the previous week, Spyglass Pharma had 2 more articles in the media than Carlsmed. MarketBeat recorded 3 mentions for Spyglass Pharma and 1 mentions for Carlsmed. Carlsmed's average media sentiment score of 1.44 beat Spyglass Pharma's score of -0.38 indicating that Carlsmed is being referred to more favorably in the media.

Company	Overall Sentiment
Carlsmed	Positive
Spyglass Pharma	Neutral

Carlsmed currently has a consensus price target of $19.33, suggesting a potential upside of 75.60%. Spyglass Pharma has a consensus price target of $45.00, suggesting a potential upside of 93.88%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Spyglass Pharma is more favorable than Carlsmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Spyglass Pharma beats Carlsmed on 7 of the 9 factors compared between the two stocks.

Get Carlsmed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CARL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CARL vs. The Competition

Export

Metric	Carlsmed	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$292.51M	$3.36B	$4.22B	$12.47B
Dividend Yield	N/A	N/A	5.92%	5.28%
P/E Ratio	-4.39	3.23	22.92	25.25
Price / Sales	5.92	337.74	162.73	77.32
Price / Cash	N/A	4.29	50.14	56.04
Price / Book	3.25	3.66	38.26	6.91
Net Income	-$29.63M	-$76.79M	$113.55M	$334.11M
7 Day Performance	12.35%	1.15%	2.60%	0.01%
1 Month Performance	3.09%	-0.18%	4.67%	1.17%
1 Year Performance	N/A	55.03%	16.53%	30.68%

Carlsmed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CARL Carlsmed	2.7992 of 5 stars	$11.01 +2.3%	$19.33 +75.6%	N/A	$292.51M	$50.51M	N/A	100	Positive News Gap Down High Trading Volume
TNDM Tandem Diabetes Care	2.5694 of 5 stars	$15.48 -16.2%	$30.16 +94.8%	-43.5%	$1.06B	$1.01B	N/A	2,500	Gap Down High Trading Volume
BFLY Butterfly Network	2.7611 of 5 stars	$4.16 -2.0%	$5.56 +33.9%	+65.4%	$1.06B	$97.61M	N/A	460	Gap Down
INMD InMode	1.8193 of 5 stars	$13.96 +0.3%	$16.00 +14.6%	-5.5%	$884.49M	$370.49M	10.26	480
BVS Bioventus	4.1512 of 5 stars	$10.50 -1.4%	$14.00 +33.3%	N/A	$873.13M	$568.09M	14.00	1,200	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CARL) was last updated on 5/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Carlsmed (CARL) Competitors

CARL vs. TNDM, BFLY, INMD, BVS, and SGP

How does Carlsmed compare to Tandem Diabetes Care?

Summary

How does Carlsmed compare to Butterfly Network?

Summary

How does Carlsmed compare to InMode?

Summary

How does Carlsmed compare to Bioventus?

Summary

How does Carlsmed compare to Spyglass Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARL vs. The Competition

Carlsmed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Carlsmed (CARL) Competitors

CARL vs. TNDM, BFLY, INMD, BVS, and SGP

How does Carlsmed compare to Tandem Diabetes Care?

Is TNDM or CARL more profitable?

Do analysts rate TNDM or CARL?

Does the media prefer TNDM or CARL?

Which has better valuation and earnings, TNDM or CARL?

Summary

How does Carlsmed compare to Butterfly Network?

Which has better valuation and earnings, BFLY or CARL?

Is BFLY or CARL more profitable?

Does the media prefer BFLY or CARL?

Do analysts rate BFLY or CARL?

Do insiders and institutionals have more ownership in BFLY or CARL?

Summary

How does Carlsmed compare to InMode?

Which has stronger earnings & valuation, CARL or INMD?

Is CARL or INMD more profitable?

Does the media refer more to CARL or INMD?

Do analysts prefer CARL or INMD?

Do institutionals and insiders have more ownership in CARL or INMD?

Summary

How does Carlsmed compare to Bioventus?

Do institutionals and insiders have more ownership in CARL or BVS?

Which has stronger earnings & valuation, CARL or BVS?

Is CARL or BVS more profitable?

Does the media refer more to CARL or BVS?

Do analysts prefer CARL or BVS?

Summary

How does Carlsmed compare to Spyglass Pharma?

Which has preferable earnings and valuation, CARL or SGP?

Is CARL or SGP more profitable?

Does the media refer more to CARL or SGP?

Do analysts prefer CARL or SGP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CARL vs. The Competition

Carlsmed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools